The cross-sectional nature of this proof-of-concept study provides support for a future longitudinal study to investigate the within and between subject changes over time (especially for the periarteriole CFZs) and as well as the association with blood-based and brain AD biomarkers (PET Aβ and tau SUVR). Here, MAPT is linked to Alzheimer disease.